# 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

> **NCT03113617** · PHASE2 · COMPLETED · sponsor: **Andrei Iagaru** · enrollment: 44 (actual)

## Conditions studied

- Stage II Prostate Adenocarcinoma
- Stage III Prostate Adenocarcinoma
- Stage IV Prostate Adenocarcinoma

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03113617
- **Lead sponsor:** Andrei Iagaru
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-10
- **Primary completion:** 2021-12-19
- **Final completion:** 2021-12-19
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113617, "68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03113617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*